[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Mar 31, 2032 → May 31, 2032
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 1, 2026 to Nov 1, 2026 Show 4 more changesShow less
    • Primary and study completion pushed from Mar 31, 2032 to May 31, 2032
    • Interventions: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one (Drug), EnhanceAR-Seq (Diagnostic Test), FTT-PET/CT… to 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one (Drug), EnhanceAR-Seq (Diagnostic Test), FTT-PET/CT…
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 10 of 10 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (FTT-PET) as a PARP inhibitor (PARPi) therapy predictive imaging biomarker and the use of EnhanceAR-Seq (ctDNA) in predicting response to therapy and to identify genomic alterations associated with resistance. Furthermore, to correlate changes in ctDNA and imaging (FTT-PET and standard of care imaging) to understand the dynamics of tumor response.
Trial Details
NCT Number NCT07723651
Lead Sponsor Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Metastatic Prostate Cancer, Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov